Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial

This work was supported by the Spanish Ministry of Science, Innovation and Universities (PI12/01907); Spanish Network for Research in Infectious Diseases (RD16/0016/0005); Instituto de Salud Carlos III (ISCIII); and Spanish Ministry of Economy, Industry and Competitiveness. This work was also suppor...

Descripción completa

Detalles Bibliográficos
Autores: Pujol, Miquel, Miró, José-María, Shaw, Evelyn, Aguado, Jose-María, San-Juan, Rafael, Puig-Asensio, Mireia, Pigrau, Carles, Calbo Sebastián, Esther, Montejo, Miguel, Rodriguez-Álvarez, Regino, Garcia-Pais, María-Jose, Pintado, Vicente, Escudero-Sánchez, Rosa, Lopez-Contreras, Joaquín, Morata, Laura, Montero, Milagros, Andrés, Marta, Pasquau, Juan, Arenas, María-del-Mar, Padilla, Belén, Murillas, Javier, Jover-Sáenz, Alfredo, López-Cortes, Luis-Eduardo, García-Pardo, Graciano, Gasch, Oriol, Videla, Sebastian, Hereu, Pilar, Tebé, Cristian, Pallarès, Natalia, Sanllorente, Mireia, Domínguez, María-Ángeles, Càmara, Jordi, Ferrer, Anna, Padullés, Ariadna, Cuervo, Guillermo, Carratalà, Jordi, MRSA Bacteremia (BACSARM) Trial Investigators
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:20.500.12328/2666
Acceso en línea:http://hdl.handle.net/20.500.12328/2666
https://dx.doi.org/10.1093/cid/ciaa1081
Access Level:acceso abierto
Palabra clave:Endocarditis
Bacterièmia
Daptomicina
Fosfomicina
Estafilococ aureus resistent a la meticil·lina
Bacteriemia
Estafilococo aureus resistente a la meticilina
Bacteremia
Daptomycin
Fosfomycin
Methicillin-resistant staphylococcus aureus
61
id ES_0bd4e94fcbb74ee2330f111aef23b57c
oai_identifier_str oai:recercat.cat:20.500.12328/2666
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial
title Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial
spellingShingle Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial
Pujol, Miquel
Endocarditis
Bacterièmia
Daptomicina
Fosfomicina
Estafilococ aureus resistent a la meticil·lina
Endocarditis
Bacteriemia
Daptomicina
Fosfomicina
Estafilococo aureus resistente a la meticilina
Endocarditis
Bacteremia
Daptomycin
Fosfomycin
Methicillin-resistant staphylococcus aureus
61
title_short Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial
title_full Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial
title_fullStr Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial
title_full_unstemmed Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial
title_sort Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial
dc.creator.none.fl_str_mv Pujol, Miquel
Miró, José-María
Shaw, Evelyn
Aguado, Jose-María
San-Juan, Rafael
Puig-Asensio, Mireia
Pigrau, Carles
Calbo Sebastián, Esther
Montejo, Miguel
Rodriguez-Álvarez, Regino
Garcia-Pais, María-Jose
Pintado, Vicente
Escudero-Sánchez, Rosa
Lopez-Contreras, Joaquín
Morata, Laura
Montero, Milagros
Andrés, Marta
Pasquau, Juan
Arenas, María-del-Mar
Padilla, Belén
Murillas, Javier
Jover-Sáenz, Alfredo
López-Cortes, Luis-Eduardo
García-Pardo, Graciano
Gasch, Oriol
Videla, Sebastian
Hereu, Pilar
Tebé, Cristian
Pallarès, Natalia
Sanllorente, Mireia
Domínguez, María-Ángeles
Càmara, Jordi
Ferrer, Anna
Padullés, Ariadna
Cuervo, Guillermo
Carratalà, Jordi
MRSA Bacteremia (BACSARM) Trial Investigators
author Pujol, Miquel
author_facet Pujol, Miquel
Miró, José-María
Shaw, Evelyn
Aguado, Jose-María
San-Juan, Rafael
Puig-Asensio, Mireia
Pigrau, Carles
Calbo Sebastián, Esther
Montejo, Miguel
Rodriguez-Álvarez, Regino
Garcia-Pais, María-Jose
Pintado, Vicente
Escudero-Sánchez, Rosa
Lopez-Contreras, Joaquín
Morata, Laura
Montero, Milagros
Andrés, Marta
Pasquau, Juan
Arenas, María-del-Mar
Padilla, Belén
Murillas, Javier
Jover-Sáenz, Alfredo
López-Cortes, Luis-Eduardo
García-Pardo, Graciano
Gasch, Oriol
Videla, Sebastian
Hereu, Pilar
Tebé, Cristian
Pallarès, Natalia
Sanllorente, Mireia
Domínguez, María-Ángeles
Càmara, Jordi
Ferrer, Anna
Padullés, Ariadna
Cuervo, Guillermo
Carratalà, Jordi
MRSA Bacteremia (BACSARM) Trial Investigators
author_role author
author2 Miró, José-María
Shaw, Evelyn
Aguado, Jose-María
San-Juan, Rafael
Puig-Asensio, Mireia
Pigrau, Carles
Calbo Sebastián, Esther
Montejo, Miguel
Rodriguez-Álvarez, Regino
Garcia-Pais, María-Jose
Pintado, Vicente
Escudero-Sánchez, Rosa
Lopez-Contreras, Joaquín
Morata, Laura
Montero, Milagros
Andrés, Marta
Pasquau, Juan
Arenas, María-del-Mar
Padilla, Belén
Murillas, Javier
Jover-Sáenz, Alfredo
López-Cortes, Luis-Eduardo
García-Pardo, Graciano
Gasch, Oriol
Videla, Sebastian
Hereu, Pilar
Tebé, Cristian
Pallarès, Natalia
Sanllorente, Mireia
Domínguez, María-Ángeles
Càmara, Jordi
Ferrer, Anna
Padullés, Ariadna
Cuervo, Guillermo
Carratalà, Jordi
MRSA Bacteremia (BACSARM) Trial Investigators
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Endocarditis
Bacterièmia
Daptomicina
Fosfomicina
Estafilococ aureus resistent a la meticil·lina
Endocarditis
Bacteriemia
Daptomicina
Fosfomicina
Estafilococo aureus resistente a la meticilina
Endocarditis
Bacteremia
Daptomycin
Fosfomycin
Methicillin-resistant staphylococcus aureus
61
topic Endocarditis
Bacterièmia
Daptomicina
Fosfomicina
Estafilococ aureus resistent a la meticil·lina
Endocarditis
Bacteriemia
Daptomicina
Fosfomicina
Estafilococo aureus resistente a la meticilina
Endocarditis
Bacteremia
Daptomycin
Fosfomycin
Methicillin-resistant staphylococcus aureus
61
description This work was supported by the Spanish Ministry of Science, Innovation and Universities (PI12/01907); Spanish Network for Research in Infectious Diseases (RD16/0016/0005); Instituto de Salud Carlos III (ISCIII); and Spanish Ministry of Economy, Industry and Competitiveness. This work was also supported by the European Development Regional Fund “A way to achieve Europe,” Operational Programme Intelligent Growth 2014–2020; Spanish Clinical Research Network (SCReN), co-financed by the Plan Nacional de I+D and ISCIII, Subdirección General de Evaluación y Fomento de la Investigación (PT13/0002/0007); and the Grupo de Estudio de la Infección Relacionada con la Asistencia Sanitaria. J. M.-M. received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques Agust Pi i Sunyer, Barcelona, Spain, during 2017–2021.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12328/2666
https://dx.doi.org/10.1093/cid/ciaa1081
url http://hdl.handle.net/20.500.12328/2666
https://dx.doi.org/10.1093/cid/ciaa1081
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clinical Infectious Diseases
72;9
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403249896849408
spelling Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trialPujol, MiquelMiró, José-MaríaShaw, EvelynAguado, Jose-MaríaSan-Juan, RafaelPuig-Asensio, MireiaPigrau, CarlesCalbo Sebastián, EstherMontejo, MiguelRodriguez-Álvarez, ReginoGarcia-Pais, María-JosePintado, VicenteEscudero-Sánchez, RosaLopez-Contreras, JoaquínMorata, LauraMontero, MilagrosAndrés, MartaPasquau, JuanArenas, María-del-MarPadilla, BelénMurillas, JavierJover-Sáenz, AlfredoLópez-Cortes, Luis-EduardoGarcía-Pardo, GracianoGasch, OriolVidela, SebastianHereu, PilarTebé, CristianPallarès, NataliaSanllorente, MireiaDomínguez, María-ÁngelesCàmara, JordiFerrer, AnnaPadullés, AriadnaCuervo, GuillermoCarratalà, JordiMRSA Bacteremia (BACSARM) Trial InvestigatorsEndocarditisBacterièmiaDaptomicinaFosfomicinaEstafilococ aureus resistent a la meticil·linaEndocarditisBacteriemiaDaptomicinaFosfomicinaEstafilococo aureus resistente a la meticilinaEndocarditisBacteremiaDaptomycinFosfomycinMethicillin-resistant staphylococcus aureus61This work was supported by the Spanish Ministry of Science, Innovation and Universities (PI12/01907); Spanish Network for Research in Infectious Diseases (RD16/0016/0005); Instituto de Salud Carlos III (ISCIII); and Spanish Ministry of Economy, Industry and Competitiveness. This work was also supported by the European Development Regional Fund “A way to achieve Europe,” Operational Programme Intelligent Growth 2014–2020; Spanish Clinical Research Network (SCReN), co-financed by the Plan Nacional de I+D and ISCIII, Subdirección General de Evaluación y Fomento de la Investigación (PT13/0002/0007); and the Grupo de Estudio de la Infección Relacionada con la Asistencia Sanitaria. J. M.-M. received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques Agust Pi i Sunyer, Barcelona, Spain, during 2017–2021.Background: We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. Methods: A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy. Results: Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93–1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018). Conclusions: Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events.info:eu-repo/semantics/publishedVersionOxford University Press2020info:eu-repo/semantics/article9http://hdl.handle.net/20.500.12328/2666https://dx.doi.org/10.1093/cid/ciaa1081reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésClinical Infectious Diseases72;9This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.comhttps://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:20.500.12328/26662026-05-29T05:05:01Z
score 15,811543